Quantitative detection of amyloid-β peptides by mass spectrometry: State of the art and clinical applications

Pauline Bros, Vincent Delatour, Jérôme Vialaret, Béatrice Lalere, Nicolas Barthelemy, Audrey Gabelle, Sylvain Lehmann, Christophe Hirtz

Research output: Contribution to journalReview article

20 Scopus citations


Alzheimer's disease (AD) is the most common form of dementia in humans, and a major public health concern with 35 million of patients worldwide. Cerebrospinal fluid (CSF) biomarkers being early diagnostic indicators of AD, it is essential to use the most efficient analytical methods to detect and quantify them accurately. These biomarkers, and more specifically amyloid-β (Aβ) peptides, are measured in routine clinical practice using immunoassays. However, there are several limits to this immunodetection in terms of specificity and multiplexing of the multiple isoforms of the Aβ peptides. To overcome these issues, the quantification of these analytes by mass spectrometry (MS) represents an interesting alternative, and several assays have been described over the past years. This article reviews the different Aβ peptides quantitative MS-based approaches published so far, compares their pre-analytical phase, and the different quantitative strategies implemented that might be suitable for clinical applications.

Original languageEnglish
Pages (from-to)1483-1493
Number of pages11
JournalClinical Chemistry and Laboratory Medicine
Issue number10
StatePublished - Sep 1 2015
Externally publishedYes


  • Alzheimer
  • amyloid-β
  • biomarkers
  • clinical chemistry
  • mass spectrometry
  • quantification

Fingerprint Dive into the research topics of 'Quantitative detection of amyloid-β peptides by mass spectrometry: State of the art and clinical applications'. Together they form a unique fingerprint.

  • Cite this